EMA pins lack of long-term data as rationale for Novartis’ failed Vijoice bid
Pharmaceutical Technology
MARCH 14, 2024
The EMA raised concerns about the lack of long-term data for Novartis Vijoice in its initial bid, as the Swiss company prepares for a new regulatory submission.
Let's personalize your content